P/E at 31.67 vs Industry's 37.19: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 31.67, which is approximately 15% below the Pharmaceuticals & Biotechnology industry average of 37.19. This discount suggests the market is pricing in either a relative earnings risk or a more cautious outlook compared to its peers. The sector’s elevated P/E reflects strong growth expectations, but Dr Reddys appears to be valued more conservatively, possibly due to recent performance trends or sector-specific headwinds. This valuation gap raises the question — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating?

Performance Across Timeframes: Mixed Momentum Signals

Examining returns over various periods reveals a complex performance profile. Over the past year, Dr Reddys Laboratories Ltd has delivered a modest 0.50% gain, outperforming the Sensex’s 9.87% decline in the same period. This relative strength is more pronounced in shorter timeframes: the stock gained 1.54% on the latest trading day, outpacing the Sensex’s 0.46% loss, and rose 2.42% over the past week versus a 2.81% drop in the benchmark.

However, the three-month return tells a different story, with the stock falling 9.81%, underperforming the Sensex’s 5.60% decline. This divergence suggests recent pressures have weighed more heavily on Dr Reddys than on the broader market — is this a temporary setback or indicative of deeper challenges? Year-to-date, the stock is down 2.34%, again outperforming the Sensex’s 15.00% fall, while longer-term returns over three and five years remain positive at 11.10% and 27.16% respectively, both ahead of the Sensex’s 10.03% and 21.92% gains.

Moving Average Configuration: Signs of a Partial Recovery

The technical picture for Dr Reddys Laboratories Ltd is nuanced. The stock currently trades above its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short- to medium-term strength. However, it remains below the 200-day moving average, which often serves as a key indicator of long-term trend direction. This configuration suggests a recent bounce within a broader downtrend, reflecting tentative recovery attempts that have yet to fully reverse the longer-term weakness. The stock’s three-day consecutive gains, amounting to a 3.33% rise, reinforce this short-term momentum — is this a genuine recovery or a relief rally that will fade at the 200 DMA?

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Out of 28 stocks that have declared results, 13 reported positive outcomes, 11 were flat, and 4 posted negative results. This distribution indicates a sector grappling with uneven performance, which may be influencing investor sentiment towards Dr Reddys Laboratories Ltd. The stock’s relative valuation discount and recent underperformance over three months could be partly attributed to this broader sector volatility — how will sector dynamics shape the stock’s near-term trajectory?

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Dr Reddys Laboratories Ltd. This rating was updated on 13 Jul 2026, reflecting the evolving data landscape. The current Mojo Score stands at 36.0, with a Sell grade, indicating a shift in assessment. The rating change aligns with the observed valuation discount, mixed performance signals, and technical configuration. This reassessment invites investors to consider the implications of the updated rating — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Market Capitalisation and Trading Activity

With a market capitalisation of approximately ₹1,03,613.04 crores, Dr Reddys Laboratories Ltd is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector. The stock has demonstrated resilience in recent trading sessions, gaining 1.54% on the latest day and outperforming the sector by 1.43%. It has also recorded a three-day consecutive gain streak, rising 3.33% in that period. The stock opened at ₹1240.35 and has maintained this level during the session, reflecting steady investor interest despite broader market fluctuations.

Collective Data Insights: A Cautious Outlook

The combination of a valuation discount relative to the sector, mixed performance across timeframes, and a technical setup indicating short-term strength within a longer-term downtrend paints a cautious picture for Dr Reddys Laboratories Ltd. The sector’s uneven results and the recent rating reassessment further underscore the need for careful analysis. While the stock has outperformed the Sensex over one year and year-to-date, the sharper three-month decline and inability to surpass the 200-day moving average suggest challenges remain — what does this mean for investors navigating the current market environment?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today